Holen Sie sich die Stockscreener-App
468.58
0.16%
-0.73
Handel nachbörslich:
475.42
6.84
+1.46%
Schlusskurs vom Vortag:
$469.31
Offen:
$474.34
24-Stunden-Volumen:
1.01M
Relative Volume:
0.93
Marktkapitalisierung:
$61.42B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-189.71
EPS:
-2.47
Netto-Cashflow:
$-52.09M
1W Leistung:
+3.32%
1M Leistung:
+7.72%
6M Leistung:
+96.27%
1J Leistung:
+78.91%
1-Tages-Spanne:
$465.16
$474.34
1-Wochen-Bereich:
$444.65
$484.21
52-Wochen-Spanne:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
468.58 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.37 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.20 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
763.52 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.67 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Top Pharmaceutical Stocks To Follow TodaySeptember 10th - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week HighWhat's Next? - MarketBeat
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com
SCS Capital Management LLC Purchases New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharma Announces $500M Convertible Notes Offering - MSN
Parkman Healthcare Partners LLC Has $18.62 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Pharmaceutical Stocks To Add to Your WatchlistSeptember 9th - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Voleon Capital Management LP - MarketBeat
Hereditary Transthyretin Amyloidosis (hATTR) Market New Product Development & Latest Trends - openPR.com
EP Wealth Advisors LLC Makes New $269,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Focus Partners Advisor Solutions LLC - MarketBeat
Alnylam prices $575M convertible senior notes - MSN
Alnylam prices $575 million convertible notes offering - Investing.com
Alnylam announces pricing of upsized offering of $575 million convertible senior notes due 2028 - MarketScreener
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes - Business Wire
Eventide Asset Management LLC Sells 73,968 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Cinctive Capital Management LP - MarketBeat
Alnylam Pharmaceuticals stock hits all-time high at 470.0 USD By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals stock hits all-time high at 470.0 USD - Investing.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After HELIOS-B Study Reveals Long-Term AMVUTTRA Benefits - simplywall.st
Alnylam (ALNY) should rally into $479-$494 before correction start - FXStreet
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases - GlobeNewswire Inc.
EFG Asset Management North America Corp. Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam commences $500 million convertible notes offering - Investing.com
Alnylam Launches $500 Million Convertible Notes Offering - MarketScreener
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes - Business Wire
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? - sharewise.com
BMO Capital raises Alnylam Pharmaceuticals stock price target on Zilebesiran potential - Investing.com Canada
Jacobs Levy Equity Management Inc. Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
AQR Capital Management LLC Buys 14,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Canada Pension Plan Investment Board - MarketBeat
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA - simplywall.st
Is Alnylam Pharmaceuticals Inc. a defensive stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - خودرو بانک
Is Alnylam Pharmaceuticals Inc. exposed to political riskJuly 2025 Decliners & Community Consensus Trade Signals - خودرو بانک
What are Alnylam Pharmaceuticals Inc.’s earnings expectationsEarnings Beat & Safe Entry Point Alerts - خودرو بانک
OMERS ADMINISTRATION Corp Decreases Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Intraday pattern recognizer results for Alnylam Pharmaceuticals Inc.2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performance2025 Year in Review & Momentum Based Trading Ideas - Newser
Published on: 2025-09-06 00:28:49 - خودرو بانک
Can Alnylam Pharmaceuticals Inc. be the next market leader2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
What to expect from Alnylam Pharmaceuticals Inc. in the next 30 days2025 Year in Review & Fast Exit and Entry Strategy Plans - Newser
Published on: 2025-09-05 14:03:59 - Newser
How to use a screener to detect Alnylam Pharmaceuticals Inc. breakoutsPortfolio Performance Summary & Free Fast Gain Swing Trade Alerts - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.Rate Cut & Safe Entry Point Identification - Newser
How high can Alnylam Pharmaceuticals Inc. stock goTrend Reversal & Reliable Trade Execution Plans - Newser
Point72 Europe London LLP Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Multi asset correlation models including Alnylam Pharmaceuticals Inc.GDP Growth & AI Forecast Swing Trade Picks - Newser
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.23%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):